Dr. Armin Ghobadi, MD

Dr. Ghobadi practices at Barnes-Jewish Hospital in Saint Louis, Missouri, part of BJC Health.

Dr. Ghobadi's NPI, 1609085356, was assigned on May 21, 2007. Dr. Ghobadi holds Missouri license 2011001452.

Dr. Ghobadi's primary practice is Barnes-Jewish Hospital, at One Barnes-Jewish Hospital Plaza, Saint Louis, MO 63110 in St. Louis City. The practice phone is (314) 747-3000. Dr. Ghobadi also practices at Barnes-Jewish Hospital, 1 Barnes Jewish Hospital Plz, Saint Louis, MO 63110.

Dr. Ghobadi's primary practice is Barnes-Jewish Hospital in Saint Louis, Missouri, part of BJC Health. Dr. Ghobadi is also affiliated with Barnes-Jewish West County Hospital. The medical group on file is WashU Medicine Psychiatry. Dmand AI also links Dr. Ghobadi to 3 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Ghobadi practices, 6 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Ghobadi's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Ghobadi is licensed in Missouri.

CMS data shows 2,467 Medicare services from Dr. Ghobadi across 17 procedure codes in 2024, for 220 Medicare patients. Medicare paid $81,251 for them.

CMS counts 220 Medicare patients who saw Dr. Ghobadi in 2024. The largest group is 65 to 74, with 103 patients. 75% of them have high blood pressure, and 69% have high cholesterol. 9% are also on Medicaid. Their average risk score is 3.01, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Ghobadi's median patient age at 71, with 40% women.

In 2024, Dr. Ghobadi wrote 979 Medicare Part D claims for 91 patients. 82% of them were for generic drugs. CMS names the drug for 695 of them, across 32 drugs with 11 or more claims each, at $1,208,740 in total drug cost. In 2023, CMS named 660 claims across 28 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Ghobadi for performance year 2024, reported as part of a group. Dr. Ghobadi accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Ghobadi as offering telehealth.

Dmand AI links 87 papers to Dr. Ghobadi, published from 2011 to 2025. 2019 was the busiest year, with 10. The most frequent topics are Immunotherapy, Adoptive, Antigens, CD19 and Lymphoma, Large B-Cell, Diffuse. Dr. Ghobadi has published most often in Blood Adv. Dr. Ghobadi's most frequent co-authors are John F. Dipersio, MD, Frederick Lundry Locke, MD and Amanda Fishback Cashen, MD.

Dmand AI links Dr. Ghobadi to 10 clinical trials, 4 of them phase 1 studies. 4 are still active or recruiting. Conditions studied include Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes and Precursor Cell Lymphoblastic Leukemia-Lymphoma. Washington University School of Medicine sponsors the most, 6.

CMS Open Payments shows 75 general payments to Dr. Ghobadi from 12 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 74% of the total. Kite Pharma, Inc. paid the most, $34,429. It also lists 1 research payment totaling $3,773 in 2025.